Clinical trial NCT05589714: Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
Official title: Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Inherited Retinal Degeneration
Retinitis Pigmentosa
Keywords: Inherited Retinal Degeneration
Lead sponsor: Jaeb Center for Health Research
Sponsor class: OTHER
Collaborators: name: Foundation Fighting Blindness
First posted: 2022-10-21
Enrollment: 1500
Sex: ALL
Minimum age (years): 4
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population includes patients with gene-related retinal degeneration. The universal registry is open to rare RD genes, to cross-sectionally characterize patients within rare RD genes (mild, moderate, and severe vision loss), so they are ready to be enrolled into a subsequent universal longitudinal natural history study as their gene is selected.

Brief summary: This is an international, multicenter study with two components:

Registry

* A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection
* Enrollment is open to all genes on the RD Rare Gene List

Natural History Study

* A prospective, standardized, longitudinal Natural History Study
* Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows.

Registry Objectives

1. Genotype Characterization
2. Cross-Sectional Phenotype Characterization (within gene)
3. Establish a Link to My Retina Tracker Registry (MRTR)
4. Ancillary Exploratory Studies - Pooling of Genes

Natural History Study Objectives

1. Natural History (within gene)
2. Structure-Function Relationship (within gene)
3. Risk Factors for Progression (within gene)
4. Ancillary Exploratory Studies - Pooling of Genes

Detailed description: This study includes multiple phases.

1. Screening Phase

   The patient's current genetic report will be reviewed. Genetic testing will not be performed in this study. A prior conclusive genetic test will be assessed for screening analysis. Having at least one gene on the RD Rare Gene List meets one of the eligible Genetic Screening Criteria and other eligibility criteria can be evaluated based on medical history.
2. Genetic Screening Phase:

   Genetic reports for participants enrolled into the genetic screening phase will be uploaded to study website for review and confirmation by Central Genetics Auditor (CGA) as meeting Genetic Screening Criteria.Participants confirmed as meeting those criteria will be considered enrolled into the Registry.
3. Registry Phase:

   The flow of participants who are enrolled into the Registry depends on whether their causal gene is designated as a Natural History Study (NHS) Target Gene. If they are not Designated as NHS Target Gene, they will receive annual phone calls up to 48 months from the Registry/Screening visit or until the gene is designated as NHS Target Gene. If they are Designated as NHS Target Gene participants will be considered pending enrollment into the NHS.

   The Registry will establish genetically and clinically well-characterized cohorts of patients across hundreds of genetic variants associated with retinal dystrophy (RD). Characterization of these patients will accelerate eligibility screening for the Natural History Study, provide cross-sectional data on phenotype-genotype associations, and contribute to our knowledge of pathogenicity of these rare disease-causing variants.
4. Natural History Study (NHS) Phase

Participants pending enrollment will return to the clinic for the NHS Enrollment/Baseline Visit and return to the clinic for follow-up visits.

The Natural History Study will accelerate the identification and development of sensitive, reliable outcome measures for clinical trials, which will facilitate development of treatments for retinal dystrophies due to disease-causing genetic variants. The expected impact of the Natural History Study is as follows:

1. Describe the natural history of retinal degeneration in patients with rare disease-causing genetic variants
2. Identify sensitive structural and functional outcome
3. Identify well-defined subpopulations for future clinical trials of investigative treatments for rare inherited retinal degeneration

Eligibility criteria: Inclusion Criteria: Participants must meet all the following inclusion criteria at the Registry/Screening Visit to be eligible to enroll into the genetic screening phase:

1. Willing to participate in the study and able to communicate consent during the consent process
2. Willing and able to complete all applicable Registry/Screening Visit assessments
3. Age ≥ 4 years
4. Must have a single gene on the RD Rare Gene List which meets one of the Genetic Screening Criteria below based on a genetic report\* from a clinically certified lab (or from a research lab which has been approved by the study Genetics Committee):

Inheritance Pattern is Recessive and has at least 2 disease-causing variants which are homozygous or heterozygous in trans

OR

Inheritance Pattern is Recessive and has 2 disease-causing variants with unknown phase and meets all the following additional informatic criteria that is consistent with likely segregation in trans:

1. Investigator confirms genotype and phenotype are consistent with autosomal recessive inheritance
2. The 2 disease-causing variants have not been reported in cis in variant databases
3. No additional potentially pathogenic variants were found on the gene (and the sequencing data for the gene were sufficiently robust to detect any additional potentially pathogenic variants)
4. No potentially pathogenic variants were found in other common, likely candidate genes for the proposed condition

OR

Inheritance Pattern is Dominant, X-linked, or Mitochondrial and has at least 1 disease-causing variant

Both eyes must meet the following criteria at the Registry/Screening Visit to enroll into the genetic screening phase:

1. Both eyes must have a clinical diagnosis of retinal dystrophy
2. Both eyes must permit good quality photographic imaging (e.g., but not limited to, clear ocular media, adequate pupil dilation, stable fixation)

Exclusion Criteria:

Participants must not meet any of the following exclusion criteria at the Registry/Screening Visit to be eligible to enroll into the genetic screening phase:

1. History of more than 1 year of cumulative treatment, at any time, with an agent associated with pigmentary retinopathy including amiodarone, chloroquine, deferoxamine, hydroxychloroquine, pentosan polysulfate, tamoxifen, and deferoxamine Note: Since this is an observational study, pregnant women will not be specifically excluded from participation. However, minors that are pregnant shall be precluded from participation until they become the age of majority.

Ocular Exclusion Criteria:

If either eye has any of the following ocular exclusion criteria at the Registry/Screening Visit, then the participant is not eligible to enroll into the genetic screening phase:

1. Current vitreous hemorrhage
2. Current complications of pathological myopia (for example, but not limited to, myopic maculopathy including atrophy, scar, choroidal neovascularization, schisis) that could inhibit ability to obtain good quality photographic imaging
3. History of intraocular surgery (for example, but not limited to, cataract surgery, vitrectomy, penetrating keratoplasty, or LASIK) within 3 months of Registry/Screening Visit
4. Current or any history of confirmed diagnosis of glaucoma (for example, but not limited to, glaucomatous VF changes or nerve changes, or history of glaucoma filtering surgery)
5. Current or any history of retinal vascular occlusion or proliferative diabetic retinopathy
6. History or current evidence of ocular disease that, in the opinion of the Investigator, may confound assessment of visual function (for example, but not limited to, tractional or rhegmatogenous retinal detachment, any vitreoretinal surgery, retinal vascular occlusion, proliferative diabetic retinopathy)
7. The following medications and treatments are prohibited as they can affect progression of retinitis pigmentosa (RP). The participant must not have received the following treatments:

   Any use of ocular stem cell or gene therapy Any treatment with ocriplasmin Treatment with Ozurdex (dexamethasone), Iluvien, or Yutiq (fluocinolone acetonide) intravitreal implant
8. The following medications and treatments are excluded within the specified timeframe:

Treatment with an ophthalmic oligonucleotide within the last 9 months (last treatment date is less than 9 months prior to Registry/Screening Visit date)

Treatment with any other product within five times the expected half-life of the product (time from last treatment date to Registry/Screening Visit date is at least 5 times the half-life of the given product)

Primary outcomes:
measure: Functional Outcome: Characterize change using Visual field sensitivity measured with quantitative topographic analysis (hill of vision [HOV])
timeFrame: Baseline and every year until study completion (4 years)
measure: Functional Outcome: Characterize Change Using Early Treatment of Diabetic Retinopathy Study (ETDRS) / HOTV Best Corrected Visual Acuity (BCVA) letter score
timeFrame: Baseline and every year until study completion (4 years)
measure: Functional Outcome: Characterize Change Using Low visual acuity test - for participants unable to see ETDRS letters
timeFrame: Baseline and every year until study completion (4 years)
measure: Functional Outcome: Characterize Change Using ETDRS/HOTV best corrected low luminance visual acuity letter score
timeFrame: Baseline and every year until study completion (4 years)
measure: Functional Outcome: Characterize Change in Mean retinal sensitivity
timeFrame: Baseline and every year until study completion (4 years)
measure: Functional Outcome: Characterize Change in Contrast sensitivity function
timeFrame: Baseline and every year until study completion (4 years)
measure: Functional Outcome: Characterize Change in Retinal function using amplitudes and timing in response to rod- and cone-specific stimuli
timeFrame: Baseline and at study completion (4 years)
measure: Functional Outcome: Characterize Change in Full-field retinal sensitivity
timeFrame: Baseline and every year until study completion (4 years)
measure: Functional Outcome: Characterize Change in Color vision function
timeFrame: Baseline and every year until study completion (4 years)
measure: Structural Outcome: Characterize Change in Ellipsoid zone (EZ) area; outer nuclear layer and ganglion cell layer thicknesses
timeFrame: Baseline and every year until study completion (4 years)
measure: Structural Outcome: Characterize Change Using Qualitative and quantitative assessments of autofluorescence pattern
timeFrame: Baseline and every year until study completion (4 years)
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas, Jones Eye Institute
state: Arkansas
city: Los Angeles
country: United States
facility: USC Roski Eye Institute
state: California
city: San Francisco
country: United States
facility: University of California San Francisco
state: California
city: Jacksonville
country: United States
facility: University of Florida Health Jacksonville
state: Florida
city: Miami
country: United States
facility: University of Miami, Bascom Palmer Eye Institute
state: Florida
city: Atlanta
country: United States
facility: Emory University, Emory Eye Center
state: Georgia
city: Baltimore
country: United States
facility: Johns Hopkins University, Wilmer Eye Institute
state: Maryland
city: Boston
country: United States
facility: Harvard Univ., Massachusetts Eye and Ear Infirmary
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan, Kellogg Eye Center
state: Michigan
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Durham
country: United States
facility: Duke University, Duke Eye Center
state: North Carolina
city: Portland
country: United States
facility: Oregon Health & Science Univ., Casey Eye Institute
state: Oregon
city: Philadelphia
country: United States
facility: Center for Advanced Retinal and Ocular Therapeutics
state: Pennsylvania
city: Philadelphia
country: United States
facility: University of Pennsylvania, Scheie Eye Institute
state: Pennsylvania
city: Pittsburgh
country: United States
facility: UPMC Eye Center
state: Pennsylvania
city: Dallas
country: United States
facility: Retina Foundation of the Southwest
state: Texas
city: Houston
country: United States
facility: Baylor College of Medicine, Alkek Eye Center
state: Texas
city: Salt Lake City
country: United States
facility: University of Utah, John Moran Eye Center
state: Utah
city: Madison
country: United States
facility: University of Wisconsin Madison
state: Wisconsin
city: Milwaukee
country: United States
facility: Medical College of Wisconsin Eye Institute
state: Wisconsin
city: East Melbourne
country: Australia
facility: Centre for Eye Research Australia
state: Victoria
city: Belo Horizonte
country: Brazil
facility: INRET Clínica e Centro de Pesquisa
state: Minas Gerais
city: São Paulo
country: Brazil
facility: Instituto de Genética Ocular
state: São Paulo Province
city: Edmonton
country: Canada
facility: University of Alberta and Alberta Health Services
state: Alberta
city: Toronto
country: Canada
facility: University of Toronto, Hospital for Sick Children
state: Ontario
city: Toronto
country: Canada
facility: University Health Network
city: Helsinki
country: Finland
facility: Helsinki University Hospital
city: Paris
country: France
facility: CHNO des Quinze-Vingts
city: Jerusalem
country: Israel
facility: Hadassah-Hebrew University Medical Center
city: Brescia
country: Italy
facility: Vista Vision Eye Clinic
city: Yucatan
country: Mexico
facility: Retina and Genomics Institute
state: Merida
city: Nijmegen
country: Netherlands
facility: Radboud University Medical Center
city: Oslo
country: Norway
facility: Oslo University Hospital
city: Basel
country: Switzerland
facility: University Hospital Basel
state: Basel-Stadt
city: Lausanne
country: Switzerland
facility: University Hospital Jules-Gonin
city: London
country: United Kingdom
facility: Moorfields Eye Hospital
Study officials:
affiliation: Director, UPMC Eye Center University of Pittsburgh School of Medicine
name: José-Alain Sahel, MD
role: STUDY_CHAIR
References: